Skip to main content
Ezra Y Rosen on Muck Rack

Ezra Y Rosen

As seen in: Nature, Cell Press, Texas Medical Center, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ezra Y

Contact Ezra Y, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types

|
By Antoine Désilets, Matteo Repetto, Monica Chen Verified, Bryan Novak, Emiliano Cocco, Yelena Kemel, Pier Selenica, Allison Richards, Mark T. A. Donoghue, Dazhi Liu, Ezra Y Rosen, Aliya Khurram, Britta Weigelt, Bob Li, Rona Yaeger, Marc Ladanyi, Chaitanya Bandlamudi, Ying Liu, Maria I. Carlo, Lauren G. Banaszak, Zsofia K. Stadler, Kenneth Offit, Diana Mandelker, Alan Ho, Alexander Drilon, Yonina R. Murciano-Goroff, Soo Ryum Yang, Cristal Velilla, Alicia Latham
| Nature Verified
Abstract Loss-of-function (LOF) alterations in PTCH1 are a hallmark of basal cell carcinoma (BCC) and drive activation of the Hedgehog (Hh) signaling pathway. Hh inhibitors are approved to treat advanced BCC, but little is known about the frequency, biology, and treatment of PTCH1 alterations in other cancers. We analyzed PTCH1 LOF alterations across diverse solid tumors and evaluated outcomes of patients with non-BCC tumors who received Hh inhibitors.
Open in Who Shared Issue with article?

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

|
By Chaitanya Bandlamudi, Daniel Muldoon, Ino de Bruijn, Mingxuan Zhang, Michael V. Gormally, Emily Harrold, Subhiksha Nandakumar, Shaleigh A. Smith, Mark Jeng, Sydney Woods, Kanika Arora, Walid K. Chatila, Bastien Nguyen, Henry Walch, Jun Woo, Craig M. Bielski, Christopher H Fong, Thinh Tran, Gaofei Zhao, Miika Mehine, Sam E. Tischfield, Allison Richards, Suraj Rajendran, Hongxin Zhang, Christoph K. Kreitzer, Ronak Shah, Risha Huq, Jesse Galle, Tina Alano, Ramyasree Madupuri, Ritika Kundra, Justin Jee, Karl Pichotta, Michele Waters, Richard A. Hickman, Josephine K. Dermawan, Jie-Fu Chen, Anton Safonov, Konrad H. Stopsack, Ritesh R. Kotecha, Hira Rizvi, Claire F. Friedman, Pedram Razavi, Ezra Y Rosen, Yonina R. Murciano-Goroff, Luc G.T. Morris, James A. Fagin, Ingo K. Mellinghoff, Ping Chi, Neerav Shukla, Adam Schoenfeld, Gregory J Riely, Charles M. Rudin, Alexander Drilon, Jake Lee, Hikmat Al-Ahmadie, Gopa Iyer, Anna Varghese, Eileen M. O’Reilly, Zsofia K. Stadler, Mark E. Robson, Ed Reznik, Jianjiong Gao, Diana Mandelker, Irina Ostrovnaya, Satshil Rana, Gowtham Jayakumaran, Anita S. Bowman, Abhinita S Mohanty, Anoop Rema Balakrishnan, Aijazuddin Syed, Ryan N. Ptashkin, Jacklyn Casanova-Murphy, Debyani Chakravarty, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Helena A. Yu, Neal Rosen, Mark T.A. Donoghue, Christopher A Klebanoff, Rona Yaeger, A. Rose Brannon, Ahmet Zehir, Marc Ladanyi, Nikolaus Schultz, David B. Solit, Michael Berger Verified
| Cell Press Verified
Main text (Cancer Cell , 1–18, May 11, 2026) Due to a typesetting error, this article was initially published online with an incorrect Received date of March 4, 2025. The manuscript was originally submitted to on April 26, 2024, and subsequently transferred to on January 7, 2026. The Received date should have reflected the original submission date of April 26, 2024. The journal has now corrected the Received date online and apologizes to the authors and readers for the confusion.
Open in Who Shared Issue with article?

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

|
By Chaitanya Bandlamudi, Daniel Muldoon, Ino de Bruijn, Mingxuan Zhang, Michael V. Gormally, Emily Harrold, Subhiksha Nandakumar, Shaleigh A. Smith, Mark Jeng, Sydney Woods, Kanika Arora, Walid K. Chatila, Bastien Nguyen, Henry Walch, Jun Woo, Craig M. Bielski, Christopher H Fong, Thinh Tran, Gaofei Zhao, Miika Mehine, Sam E. Tischfield, Allison Richards, Suraj Rajendran, Hongxin Zhang, Christoph K. Kreitzer, Ronak Shah, Risha Huq, Jesse Galle, Tina Alano, Ramyasree Madupuri, Ritika Kundra, Justin Jee, Karl Pichotta, Michele Waters, Richard A. Hickman, Josephine K. Dermawan, Jie-Fu Chen, Anton Safonov, Konrad H. Stopsack, Ritesh R. Kotecha, Hira Rizvi, Claire F. Friedman, Pedram Razavi, Ezra Y Rosen, Yonina R. Murciano-Goroff, Luc G.T. Morris, James A. Fagin, Ingo K. Mellinghoff, Ping Chi, Neerav Shukla, Adam Schoenfeld, Gregory J Riely, Charles M. Rudin, Alexander Drilon, Jake Lee, Hikmat Al-Ahmadie, Gopa Iyer, Anna Varghese, Eileen M. O'Reilly, Zsofia K. Stadler, Mark E. Robson, Ed Reznik, Jianjiong Gao, Diana Mandelker, Irina Ostrovnaya, Satshil Rana, Gowtham Jayakumaran, Anita S. Bowman, Abhinita S Mohanty, Anoop Rema Balakrishnan, Aijazuddin Syed, Ryan N. Ptashkin, Jacklyn Casanova-Murphy, Debyani Chakravarty, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Helena A. Yu, Neal Rosen, Mark T.A. Donoghue, Christopher A Klebanoff, Rona Yaeger, A. Rose Brannon, Ahmet Zehir, Marc Ladanyi, Nikolaus Schultz, David B. Solit, Michael Berger Verified
| Cell Press Verified
Refers to: Keywords cancer type-specific tissue-specific driver alterations hotspots precision oncology clinical sequencing age of cancer diagnosis HLA genotype neoantigen-directed TCR therapies HLA loss of heterozygosity Introduction Cancer is a genetic disease defined by the serial acquisition of cell fitness-promoting mutations, referred to as “drivers.”1 Characterization of driver alterations is fundamental to understanding cancer pathogenesis, molecular classification of tumors, and...
Open in Who Shared Issue with article?
See all 6 licensed articles (7 Total)